Jiang Junhuang, Lu Anqi, Ma Xiangyu, Ouyang Defang, Williams Robert O
Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
Global Investment Research, Goldman Sachs, NY 10282, USA.
Int J Pharm X. 2023 Jan 23;5:100164. doi: 10.1016/j.ijpx.2023.100164. eCollection 2023 Dec.
Amorphous solid dispersion (ASD) is one of the most important strategies to improve the solubility and dissolution rate of poorly water-soluble drugs. As a widely used technique to prepare ASDs, hot-melt extrusion (HME) provides various benefits, including a solvent-free process, continuous manufacturing, and efficient mixing compared to solvent-based methods, such as spray drying. Energy input, consisting of thermal and specific mechanical energy, should be carefully controlled during the HME process to prevent chemical degradation and residual crystallinity. However, a conventional ASD development process uses a trial-and-error approach, which is laborious and time-consuming. In this study, we have successfully built multiple machine learning (ML) models to predict the amorphization of crystalline drug formulations and the chemical stability of subsequent ASDs prepared by the HME process. We utilized 760 formulations containing 49 active pharmaceutical ingredients (APIs) and multiple types of excipients. By evaluating the built ML models, we found that ECFP-LightGBM was the best model to predict amorphization with an accuracy of 92.8%. Furthermore, ECFP-XGBoost was the best in estimating chemical stability with an accuracy of 96.0%. In addition, the feature importance analyses based on SHapley Additive exPlanations (SHAP) and information gain (IG) revealed that several processing parameters and material attributes (i.e., drug loading, polymer ratio, drug's Extended-connectivity fingerprints (ECFP) fingerprints, and polymer's properties) are critical for achieving accurate predictions for the selected models. Moreover, important API's substructures related to amorphization and chemical stability were determined, and the results are largely consistent with the literature. In conclusion, we established the ML models to predict formation of chemically stable ASDs and identify the critical attributes during HME processing. Importantly, the developed ML methodology has the potential to facilitate the product development of ASDs manufactured by HME with a much reduced human workload.
无定形固体分散体(ASD)是提高难溶性药物溶解度和溶出速率的最重要策略之一。作为一种广泛用于制备ASD的技术,热熔挤出(HME)具有多种优势,包括无溶剂工艺、连续制造以及与基于溶剂的方法(如喷雾干燥)相比更高效的混合。在HME过程中,由热能和特定机械能组成的能量输入应仔细控制,以防止化学降解和残留结晶度。然而,传统的ASD开发过程采用试错法,既费力又耗时。在本研究中,我们成功构建了多个机器学习(ML)模型,以预测结晶药物制剂的非晶化以及通过HME工艺制备的后续ASD的化学稳定性。我们使用了包含49种活性药物成分(API)和多种类型辅料的760种制剂。通过评估构建的ML模型,我们发现ECFP-LightGBM是预测非晶化的最佳模型,准确率为92.8%。此外,ECFP-XGBoost在估计化学稳定性方面表现最佳,准确率为96.0%。此外,基于SHapley加法解释(SHAP)和信息增益(IG)的特征重要性分析表明,几个加工参数和材料属性(即药物负载量、聚合物比例、药物的扩展连接指纹(ECFP)指纹和聚合物的性质)对于所选模型的准确预测至关重要。此外,确定了与非晶化和化学稳定性相关的重要API子结构,结果与文献基本一致。总之,我们建立了ML模型来预测化学稳定的ASD的形成,并识别HME加工过程中的关键属性。重要的是,所开发的ML方法有潜力促进通过HME制造的ASD的产品开发,同时大大减少人力工作量。